Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hung, Chih-Chiang
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Approved for marketing	N/A		Europe, Canada, RoW	Abemaciclib, LY2835219	Eli Lilly and Company	Metastatic Breast Cancer
EXPERT, NCT02889874: EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer	Recruiting	N/A	1167	Europe, RoW	Omission of radiation therapy	Breast Cancer Trials, Australia and New Zealand, Breast International Group, ETOP IBCSG Partners Foundation	Early Stage Breast Carcinoma	10/25	04/26
NCT05641571: Effects of an Exercise Intervention on Taxane-induced Peripheral Neuropathy in Breast Cancer Survivors	Not yet recruiting	N/A	88	NA	The home-based extremity exercise program	Taichung Veterans General Hospital	CIPN - Chemotherapy-Induced Peripheral Neuropathy	12/23	12/23